The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
The two-day conference and exhibition features discussions on policy frameworks, AI-led drug discovery, next-generation technologies, and global competitiveness
The facility will manufacture the critical antibiotic intermediate Amino Cephalosporanic Acid (ACA), a key component in the production of cephalosporin antibiotics
The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Government policies and competitive industry driving India’s MedTech sector for sustained double-digit growth
The PLI scheme focuses on incentivizing a strategic shift towards high-value, innovative products such as biologics, complex generics, and specialty formulations
The scheme aims to avoid disruption in supply of critical active pharmaceutical ingredients (APIs) used to make critical drugs
Through strong industry cooperation, significant investment, and smart policy backing, API manufacturing may become self-reliant
Subscribe To Our Newsletter & Stay Updated
